Vizirgianakis Stavros G. 4

What Happened Stavros G. Vizirgianakis, a director of Apyx Medical Corp. (APYX), was granted 450,000 restricted stock units (RSUs) on June 11, 2026. The grant is reported as an acquisition at $0.00 per share (typical for RSU awards). According to the filing, 150,000 of the RSUs vested immediately on the grant date; the remaining 300,000 are subject to time-based vesting over the next two years.

Key Details

• Transaction date: 2026-06-11; Form 4 filed: 2026-06-15 (timely filing).
• Transaction code: A (award/grant).
• Amount: 450,000 RSUs acquired at $0.00 per share.
• Vesting: 150,000 vested immediately on June 11, 2026; 150,000 begin vesting on the first anniversary and vest ratably over 12 months; the final 150,000 begin vesting on the second anniversary and vest ratably over 12 months—each tranche subject to continued service and award terms.
• Shares owned after transaction: not specified in the Form 4.
• No tax withholding, sale, or cashless exercise is reported in this filing.

Context This is a compensation/retention award, not an open-market purchase or sale. RSU grants are common for executives and directors; the immediate vesting of 150,000 RSUs means those units effectively converted to shares on the grant date (subject to any separate issuance/withholding not shown). The remaining RSUs will only convert to shares if the director remains in service through the applicable vesting periods.